Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kite Pharma has entered into an exclusive, worldwide license with the National Institutes of Health (NIH) for intellectual property related to a fully human anti-CD19 chimeric antigen receptor-based product candidate directed against B-cell malignancies.
Subscribe to our email newsletter
The National Cancer Institute (NCI), with Dr. James N. Kochenderfer, M.D., an investigator in the Experimental Transplantation and Immunology Branch of the NCI, is currently conducting a Phase 1 clinical trial of the product candidate in patients with B-cell malignancies under an existing Cooperative Research and Development Agreement (CRADA) between Kite and the NCI.
Kite Pharma chairman, president, and CEO Arie Belldegrun said: "The expansion of our CAR-T pipeline to include a fully human anti-CD19 chimeric antigen receptor supports our effort to maximize the potential benefit of CAR-T therapies for patients with advanced B-cell malignancies.
"As the field of T-cell therapy continues its rapid advancement, we remain committed to collaborating with the world's most distinguished institutions and accessing the most significant enabling technologies to pioneer the next generation of T-cell therapies."